AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Distribution Partnering Terms & Agreements in Pharma, Biotech & Diagnostics: 2014 to 2019 - ResearchAndMarkets.com

May 2, 2019

DUBLIN--(BUSINESS WIRE)--May 2, 2019--The “Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014 to 2019” report has been added to ResearchAndMarkets.com’s offering.

The report provides details of the latest distribution agreements announced in the pharmaceutical, biotechnology and diagnostic sectors.

This report provides the reader with the following key benefits:

  • In-depth understanding of licensing partnering deal trends since 2014
  • Insight into the terms included in a licensing agreement, together with real world clause examples
  • Identify leading licensing deals by value since 2014
  • Identify the most active licensing dealmakers since 2014
  • Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
  • Full listing of licensing deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus
  • Comprehensive access to over 4,500 licensing deals entered into by the world’s biopharma companies, together with contract documents if available
  • Detailed access to actual licensing contracts entered into by the leading fifty big pharma and big biotech companies
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Key Topics Covered

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in distribution dealmaking

2.1. Introduction

2.2. Definition of distribution deals

2.3. Trends in distribution deals since 2014

2.3.1. Distribution dealmaking by year, 2014 to 2019

2.3.2. Distribution dealmaking by phase of development since 2014

2.3.3. Distribution dealmaking by industry sector since 2014

2.3.4. Distribution dealmaking by therapy area since 2014

2.3.5. Distribution dealmaking by technology type since 2014

2.3.6. Distribution dealmaking by most active company since 2014

2.3.7. Attributes of pure distribution deals

2.3.8. Attributes of distribution in multi-component deals

2.4. Aligning partners to make the distribution agreement work

Chapter 3 - Overview of distribution deal structure

3.1. Introduction

3.2. Distribution agreement structure

3.3. Example distribution agreements

3.3.1. Case study 1: Zeltiq Aesthetics - Advance Medical

3.3.2. Case study 2: QLT - ASD Speciality Healthcare

3.4 Distribution rights as part of a wider alliance agreement

3.4.1. Case study 1: Caleco Pharma - Natac Biotech

3.4.2. Case study 2: Purdue Pharma - Transcept Pharmaceuticals

Chapter 4 - Leading distribution deals

4.1. Introduction

4.2. Top distribution deals by value

Chapter 5 - Top 25 most active distribution dealmakers

5.1. Introduction

5.2. Top 25 most active distribution dealmakers

Chapter 6 - Distribution deals including contracts directory

6.1. Introduction

6.2. Distribution deals with contracts since 2014

For more information about this report visit https://www.researchandmarkets.com/r/ido61i

View source version on businesswire.com:https://www.businesswire.com/news/home/20190502005693/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Biotechnology,Pharmaceuticals,Diagnostics

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/02/2019 12:59 PM/DISC: 05/02/2019 12:58 PM

http://www.businesswire.com/news/home/20190502005693/en